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ARTICLE
BRCA2 deﬁciency instigates cGAS-mediated
inﬂammatory signaling and confers sensitivity to
tumor necrosis factor-alpha-mediated cytotoxicity
Anne Margriet Heijink1, Francien Talens1, Lucas T. Jae2, Stephanie E. van Gijn1, Rudolf S.N. Fehrmann1,
Thijn R. Brummelkamp3,4,5 & Marcel A.T.M. van Vugt1
Loss of BRCA2 affects genome stability and is deleterious for cellular survival. Using a
genome-wide genetic screen in near-haploid KBM-7 cells, we show that tumor necrosis
factor-alpha (TNFα) signaling is a determinant of cell survival upon BRCA2 inactivation.
Speciﬁcally, inactivation of the TNF receptor (TNFR1) or its downstream effector SAM68
rescues cell death induced by BRCA2 inactivation. BRCA2 inactivation leads to pro-
inﬂammatory cytokine production, including TNFα, and increases sensitivity to TNFα.
Enhanced TNFα sensitivity is not restricted to BRCA2 inactivation, as BRCA1 or FANCD2
inactivation, or hydroxyurea treatment also sensitizes cells to TNFα. Mechanistically, BRCA2
inactivation leads to cGAS-positive micronuclei and results in a cell-intrinsic interferon
response, as assessed by quantitative mass-spectrometry and gene expression proﬁling, and
requires ASK1 and JNK signaling. Combined, our data reveals that micronuclei induced by loss
of BRCA2 instigate a cGAS/STING-mediated interferon response, which encompasses re-
wired TNFα signaling and enhances TNFα sensitivity.
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Cells are equipped with evolutionary conserved pathways todeal with DNA lesions1. These signaling pathways arecollectively called the ‘DNA damage response’ (DDR), and
constitute a complex signaling network, displaying multiple levels
of cross-talk and feed-back control. Multiple parallel kinase-
driven DDR signaling axes ensure rapid responses to DNA
lesions, whereas a complementary transcriptional DDR axis
warrants maintained signaling. Ultimately, activation of the DDR
results in an arrest of ongoing proliferation, which provides time
to repair DNA damage. In case of sustained or excessive levels of
DNA damage, the DDR can instigate a permanent cell cycle exit
(senescence) or initiate programmed cell death (apoptosis)2.
DNA damage can arise from extracellular sources, including
ultraviolet light exposure or anti-cancer treatment, and also ori-
ginates from intracellular sources, such as oxygen radicals. An
alternative source of DNA damage is defective DNA repair.
Multiple syndromes are caused by germline mutations in DNA
repair genes, which lead to accumulation of DNA damage, and
ensuing adverse phenotypes such as accelerated aging, neurode-
generation and predisposition to cancer.
For instance, homozygous hypomorphic mutations of the
DNA repair genes BRCA1 and BRCA2 are associated with
development of Fanconi anemia3,4, whereas heterozygous BRCA1
or BRCA2 mutations predispose affected individuals to early-
onset breast and ovarian cancer5–7.
Both BRCA1 and BRCA2 are key players in DNA damage
repair through homologous recombination (HR)8. BRCA1 func-
tions upstream in HR, where it controls the initiation of DNA-
end resection at sites of double-stranded breaks (DSBs), in con-
junction with CtIP and the MRN complex1,2,8. Once BRCA1 has
been recruited to sites of DNA breaks, it associates with PALB2,
which ultimately recruits BRCA2. In turn, BRCA2 controls the
loading of the RAD51 recombinase onto resected DNA ends9.
Inactivation of BRCA1, BRCA2 or other HR components
severely compromises homology-driven repair of DSBs8,10,11.
Since HR is vital to repair double-stranded breaks that sponta-
neously arise during DNA replication, functional HR is required
to maintain genomic integrity9,12–14. In line with this notion,
homozygous loss of Brca1 or Brca2 leads to accumulation of
DNA breaks, and results in activation of p53, which promotes cell
cycle arrest and activation of apoptosis and senescence pro-
grams15–18. As a result, BRCA1 or BRCA2 loss is not tolerated
during human or mouse development and leads to embryonic
lethality9,12–14. Importantly, Brca1 or Brca2 are not only essential
in the context of development, but also deletion of these genes
severely impacts proliferation in vitro, indicating that BRCA1 and
BRCA2 are intrinsically essential to cellular viability12,14,15.
In clear contrast, loss of BRCA1 or BRCA2 is apparently tol-
erated in breast and ovarian cancers affected by BRCA1 or BRCA2
mutations. It remains incompletely understood how these tumor
cells remain viable, despite their continuous accumulation of
DNA lesions19. The observation that BRCA1 or BRCA2 mutant
cancers almost invariably have inactivated TP53 points at
p53 signaling forming a barrier to cellular proliferation in the
absence of BRCA1 or BRCA2. Indeed, concomitant deletion of
Tp53 in mice delays early embryonic lethality in Brca1−/− or
Brca2−/− embryos20,21, and is required to promote tumor for-
mation22. However, Tp53 inactivation only partially rescued
embryonic lethality and cellular viability of Brca1 or Brca2
mutant cells, indicating that additional mechanisms are likely to
play a role in the survival of these cells.
Despite the extensive knowledge of DDR signaling and insight
into DNA repair mechanisms, it currently remains incompletely
clear how cells with DNA repair defects are eliminated and,
conversely, how such cells can escape clearance. Several gene
mutations have previously been described to rescue survival of
BRCA1-deﬁcient cells, but for BRCA2-deﬁcient cancer cells this
remains less clear23–27. Here, we used a haploid genomic screen
to identify gene mutations that modify cell viability in BRCA2-
inactivated cells. We ﬁnd that loss of the tumor necrosis factor-α
(TNFα) receptor, or its downstream signaling component
SAM68, rescues cytotoxicity induced by BRCA2 inactivation in
KBM-7 cells. Enhanced TNFα appears to be part of a cell-intrinsic
and cGAS/STING-dependent interferon response, triggered by
formation of micronuclei. Combined, our results describe a
mechanism by which autocrine TNFα signaling, induced by
cGAS/STING signaling upon loss of the BRCA2 tumor-
suppressor gene, limits tumor cell viability.
Results
Screening mutations that rescue BRCA2-mediated cell death.
To identify gene mutations that rescue cytotoxicity induced
by loss of BRCA2, monoclonal KBM-7 cell lines were engineered
to express doxycycline-inducible BRCA2 short hairpin RNAs
(shRNAs; Fig. 1a, Supplementary Fig. 1a). To test whether
doxycycline treatment resulted in functional inactivation of
BRCA2, we tested two previously described functions of BRCA2:
facilitating recruitment of RAD51 to sites of DNA breaks10 and
protection of stalled replication forks28. After 48 h of doxycycline
treatment, ionizing radiation (IR)-induced recruitment of RAD51
to foci was lost (Fig. 1b, Supplementary Fig. 1b). Analogously, the
ability to protect stalled replication forks, as assessed by DNA
ﬁber analysis, was weakened signiﬁcantly (Fig. 1c). Speciﬁcally,
control cells maintained nascent DNA at replication forks upon
hydroxyurea (HU)-induced replication fork stalling. In contrast,
BRCA2-depleted cells showed defective protection of stalled
forks, as indicated by decreased CldU ﬁber length after HU
treatment (Fig. 1c). Finally, analysis of cell numbers showed that
proliferation ceased from 4 days after doxycycline treatment
onwards in shBRCA2 cells, and a near-complete loss of cell via-
bility was seen in less than 2 weeks of BRCA2 depletion (Fig. 1d).
Importantly, these effects were observed with two independent
BRCA2 shRNAs. Notably, KBM-7 cells harbor a loss-of-function
TP53 mutation, and our results therefore show that p53 inacti-
vation per se does not preclude the cytotoxic effects of BRCA2
loss9,20.
The virtually complete cell death after BRCA2 depletion in the
near-haploid KBM-7 cells allowed us to use insertional
mutagenesis to screen for gene mutations that confer a survival
advantage upon BRCA2 depletion (Fig. 1e). To this end, we
mutagenized KBM-7-shBRCA2 #2 cells using a retroviral ‘gene-
trap’ vector to obtain a collection of ∼100 × 106 mutants29,30.
Massive parallel sequencing was performed on genomic DNA
isolated from cells that were allowed to grow for 19 days in the
presence of doxycycline (Supplementary Data 1). To ﬁlter out
mutations that affect doxycycline-mediated expression of
shRNAs, we performed a cross-comparison with a screen for
gene mutations that reversed cell death induced by shRNA-
mediated loss of the essential mitotic spindle component Eg5
(Supplementary Data 2)31. As expected, multiple dominant
integration hotspots identiﬁed in the shBRCA2 screen marked
doxycycline-related genes which will nullify shRNA-mediated
BRCA2 depletion, including SUPT3H, POU2F1 and NONO
(Supplementary Data 2 and Fig. 1f). Speciﬁcally in BRCA2-
depleted cells, we observed an enrichment of insertion sites in the
PAXIP1 gene, encoding PTIP, which was recently identiﬁed to
control replication fork degradation in BRCA2-inactivated cells27.
Among the most signiﬁcantly enriched gene mutations, we
identiﬁed multiple components of the TNFα receptor complex,
including TNFRSF1A (encoding TNFR1) and KHDRBS1 (encod-
ing SAM68) (Fig. 1f).
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TNFα signaling determines viability in BRCA2-depleted cells.
To assess whether BRCA2 mutations in cancers are associated
with decreased expression of identiﬁed genes, we analyzed the
serous ovarian cancers (SOC) within The Cancer Genome Atlas
(TCGA) dataset32. We speciﬁcally analyzed SOC, since BRCA2
germline mutations are most frequently found within this sub-
group of ovarian cancers. Interestingly, the TNFα pathway
component KHDRBS1 on average showed lower median mes-
senger RNA (mRNA) levels in BRCA2-mutated vs. BRCA2
wildtype (wt) tumors (Supplementary Fig. 1c). KHDRBS1 showed
a larger difference in expression level when compared to PAXIP1,
although differences for both genes were not statistically sig-
niﬁcant, likely due to the low number of BRCA2 mutant cancers.
According to literature, the KHDRBS1 gene product SAM68 is
recruited to TNFR1 upon activation with TNFα, where it func-
tions as a scaffold for nuclear factor (NF)-κB activation (Fig. 2a,
‘complex 1′)33. In a delayed response upon TNFα administration,
TNFR1 is internalized and SAM68 and RIPK1 disassociate from
the TNFα receptor. Together with FADD (Fas-associated protein
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and RIPK1 initiate activation of intrinsic caspases and thereby
promote cell death33.
To validate whether TNFR1 or SAM68 inactivation confers a
survival advantage upon BRCA2 depletion, KBM-7-shBRCA2
cells were infected with plasmids harboring shRNAs targeting
TNFR1 or SAM68 while also encoding an internal ribosome entry
site (IRES)-driven mCherry cassette (Supplementary Fig. 2a). In
line with our screening data, BRCA2-depleted KBM-7 cells that
were also depleted for TNFR1 or SAM68 showed a survival
advantage over cells only depleted for BRCA2, as judged from the
gradual increase in mCherry-positive cells (Fig. 2b, c). Notably,
TNFR1- or SAM68-depleted KBM-7 cells did not confer a
survival advantage through compromising the shRNA-induced
knockdown of BRCA2 (Supplementary Fig. 2b). In contrast,
BRCA2 depletion was nulliﬁed by small interfering RNA
(siRNA)-mediated knockdown of SUPTH3, in line with our
expectations (Supplementary Fig. 2c).
Depletion of TNFR1 or SAM68 did not reduce the total level of
DNA damage induced by BRCA2 loss, as γH2AX levels were
similar (Supplementary Fig. 2d). Moreover, loss of TNFR1 or
SAM68 did not confer a generic survival advantage, as TNFR1 or
SAM68 depletion did not rescue cytotoxicity induced by Eg5
depletion (Supplementary Fig. 2e). It should be noted that TNFα
receptor signaling controlled cell death upon BRCA2 loss was not
observed in all cell line models. When Brca2F/-:Tp53F/F mouse
embryonic ﬁbroblasts (MEFs) were infected with Cre recombi-
nase to induce loss of BRCA2 and p53, this resulted in efﬁcient
gene inactivation and interfered with cellular viability (Supple-
mentary Fig. 3a). Of note, shRNA-mediated inactivation of
TNFR1 or SAM68 did not signiﬁcantly rescue cellular survival
(Supplementary Fig. 3b,c). In line with these cells not being
responsive to TNFα receptor signaling, inactivation of Brca2 did
not confer sensitivity to recombinant TNFα (Supplementary
Fig. 3d).
Next, two triple negative breast cancer (TNBC) cell lines, BT-
549 and MDA-MB-231, were depleted for BRCA2 (Supplemen-
tary Fig. 4a). In line with our results in KBM-7 cells, BRCA2
depletion interfered with long-term survival (Supplementary
Fig. 4b). Assessing the effects of TNFR1 inactivation on survival
of BRCA2-depleted MDA-MB-231 was not feasible, because
TNFR1 appeared essential for viability in this cell line, regardless
of BRCA2 status (Supplementary Fig. 4c-e). In contrast, a stable
population of TNFR1-depleted BT-549 cells was established
(Supplementary Fig. 4f,g), and showed that TNFR1 inactivation
results in a survival beneﬁt in BRCA2-depleted BT-549 cells
(Fig. 2d, e). However, SAM68 depletion interfered with survival of
BT-549 cells independent of BRCA2 status, as hardly any cells
survived constitutive SAM68 depletion (Supplementary Fig. 4g,h).
Combined, our data show that loss of TNFR1 or SAM68 confers a
survival advantage in BRCA2-depleted cells, in situations where
TNFR1 or SAM68 are not essential for viability, suggesting a
mechanistic link between TNFα signaling and BRCA2 function in
a context-dependent fashion.
Cytokine production and TNFα signaling upon BRCA2 loss.
To further investigate the relation between BRCA2 inactivation
and TNFα signaling, we ﬁrst tested whether limiting the available
TNFα pool would alter the reduced cellular viability induced by
BRCA2 depletion. Indeed, upon addition of the TNFα-
neutralizing antibody inﬂiximab to culture media, cellular viabi-
lity of BRCA2-depleted KBM-7 cells increased (Fig. 3a). Impor-
tantly, and in line with these ﬁndings, BRCA2 depletion in KBM-
7 cells resulted in increased levels of TNFα secretion, as measured
using enzyme-linked immunosorbent assay (ELISA; Fig. 3b). Of
note, TNFα production appeared to be part of a broader panel of
upregulated pro-inﬂammatory cytokines in response to BRCA2
depletion, including interleukin (IL)-6 and IL-8 (Fig. 3b). In
contrast, the anti-inﬂammatory cytokine IL-10 was not elevated
after BRCA2 depletion (Fig. 3b).
Although the levels of TNFα reproducibly increased upon
BRCA2 loss, the overall level of TNFα was limited, and we
wondered whether this increase accounted for activation of the
TNFα signaling cascade. To test this, we measured the levels of c-
Jun N-terminal kinase (JNK) phosphorylation (p-JNK), p38
phosphorylation (p-p38), DNA double-strand break accumula-
tion (γH2AX), and PARP (poly (ADP-ribose) polymerase)
cleavage (cPARP) by immunoblotting (Fig. 3c) and ﬂow
cytometry (Fig. 3d). Clearly, BRCA2 depletion for 2, 4 or 7 days
resulted in increased levels of p-p38 and p-JNK (Fig. 3c, d). In
accordance with these observations, the levels of γH2AX and
cleaved PARP were also elevated over time upon BRCA2 loss
(Fig. 3c–e). Thus, BRCA2 loss instigates a TNFα signaling
cascade, leading to cell death in KBM-7 cells, which can be
circumvented by sequestering the levels of circulating TNFα.
BRCA2 inactivation leads to increased TNFα sensitivity. Since
the overall levels of secreted TNFα after BRCA2 depletion were
limited, we wondered whether increased cellular sensitivity to TNFα
could also play a role. To test whether BRCA2 inactivation increases
sensitivity to TNFα, BRCA2-depleted KBM-7 cells were treated
with recombinant TNFα. Indeed, BRCA2-depleted but not control-
depleted KBM-7 cells showed signiﬁcantly increased sensitivity to
recombinant TNFα (Fig. 4a). Notably, co-depletion of BRCA2 with
SAM68 or TNFR1 rescued the observed sensitivity to TNFα
(Fig. 4b, Supplementary Fig. 5a). These responses were not speciﬁc
Fig. 1 Genetic determinants of cellular survival in BRCA2-depleted KBM-7 cells. a KBM-7 cells were stably transduced with indicated doxycyline-inducible
shRNA vectors. Cells were treated with doxycycline for 3 or 5 days and lysates were immunoblotted for BRCA2 and Actin. b Quantiﬁcation of the
percentage of cells with ≥10 RAD51 foci after 5 Gy irradiation. KBM-7 cells harboring indicated shRNAs were treated with doxycycline for 96 h prior to
irradiation. Approximately 100 cells were scored per condition per replicate. Error bars indicate s.d. of two independent experiments. P values were
calculated using two-tailed Student’s t-test. c KBM-7 cells expressing shBRCA2 #2 were processed for DNA ﬁber analysis after treatment with doxycycline
for 96 h. Cells were then incubated with CldU (25 μM) for 40min to label replication tracks and subsequently treated with HU (2mM) for 4 h. CldU track
lengths are plotted for ±500 ﬁbers per condition. Median values are indicated and error bars indicate s.d. P values were calculated using two-tailed
Student’s t-test. d Indicated KBM-7 cells were plated in the presence or absence of doxycycline. At indicated time points, cell numbers were assessed. Error
bars indicate s.d. of three independent experiments. e Workﬂow of genetic screen in near-haploid KBM-7 cells. f Insertions sites identiﬁed in gene-trap
mutagenized KBM-7 cells which survived doxycycline-induced BRCA2 inactivation (shBRCA2 #2). Dots represent individual genes. The frequency of
insertions mapped to a speciﬁc gene is plotted on the x-axis. The ratio of gene-traps inserted in the sense orientation over total insertions are plotted on
the y-axis. Genes that are neutral in conferring a survival advantage in BRCA2-depleted cells have a sense/total insertion ratio of 0.5 (indicated by the red
dashed line). Insertion site ratios > 0.5 represent genes that when mutated confer survival beneﬁt to BRCA2-depleted cells. Throughout the ﬁgure, *P <
0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07927-y
4 NATURE COMMUNICATIONS |          (2019) 10:100 | https://doi.org/10.1038/s41467-018-07927-y | www.nature.com/naturecommunications
to KBM-7 cells, as increased TNFα sensitivity was also observed in a
dose-dependent manner upon BRCA2 depletion in a panel of
TNBC cell lines (Fig. 4c, Supplementary Fig.4a, 5b) and in the
colorectal cancer cell line DLD-1, in which the BRCA2 gene was
inactivated using CRISPR/Cas9 (clustered regularly interspaced
short palindromic repeats/CRISPR-associated 9) (Fig. 4d, Supple-
mentary Fig. 5c). Importantly, the increased sensitivity to TNFα in
BRCA2-depleted cells could not be attributed to changes in TNFR1
expression levels upon BRCA2 inactivation (Supplementary Fig. 5d,
e). Taken together, these results show that BRCA2 inactivation not
only induces TNFα signaling, but also results in increased TNFα
sensitivity.
In physiological conditions, TNFα-induced NF-κB pro-survival
signaling dominates apoptosis signaling34. However, sustained
activity of JNK (MAPK8), which together with the ASK1 kinase
(MAP3K5) acts downstream of the TNF receptor, can ‘overrule’
NF-κB pro-survival signaling and drive apoptosis35. Our
observation that BRCA2 depletion leads to increased JNK activity
(Fig. 3c, d) would be in line with such a mechanism. To test if
sustained activity of ASK1 or JNK kinases is required to mediate
TNFα-induced cell death in BRCA2-depleted cells, we chemically
inhibited JNK (Fig. 4e, Supplementary Fig. 5f) or ASK1 (Fig. 4f,
Supplementary Fig. 5f), in combination with TNFα treatment.
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Fig. 2 Loss of TNFR1 and SAM68 rescues cellular viability in BRCA2-depleted cancer cells. a Schematic overview of TNFR1 complex formation upon TNFα
binding, leading to cell survival (complex I) or delayed caspase activation and cell death (complex II). b Flow cytometry analysis of KBM-7-shBRCA2 #2
cells, additionally carrying indicated shRNA vectors with IRES-driven mCherry cassettes. Cells were treated with doxycycline for 14 days and percentages
of mCherry-positive cells were measured. c Indicated KBM-7-shBRCA2 cells carrying mCherry shRNA cassettes targeting TNFR1, SAM68 or a control
sequence (‘SCR’) were treated with or without doxycycline to induce BRCA2 shRNA expression. Percentages of mCherry-positive cells were measured
every 3 or 4 days for 3 weeks after start of doxycycline treatment. Ratios of mCherry-positive cells in doxycycline treated cultures vs. untreated cultures are
indicated. Per condition, at least 30,000 events were measured. d BT-549 cells, stably transduced with pLKO.tet.shBRCA2 #2, were infected with IRES
mCherry shRNA vectors as for b. Cells were treated with or without doxycycline, and percentages of mCherry-positive cells were measured. Ratios of
mCherry-positive cells at indicated time points vs. mCherry-positive percentages at day 0 are indicated. Error bars indicate s.d. of three independent
experiments. P values were calculated using two-tailed Student’s t-test. *P < 0.05, **P < 0.01 and ***P < 0.001. e Representative ﬂow cytometry plots of BT-
549-shBRCA2 #2 cells from d are shown, carrying mCherry shRNA cassette for TNFR1 #2. Cells were treated for 15 days with or without doxycycline and
gated based on mCherry positivity. Numbers indicate the percentages of mCherry-positive cells
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Fig. 3 BRCA2 depletion results in increased TNFα signaling. a KBM-7 cells harboring indicated shRNAs were treated with doxycycline for 48 h and
subsequently plated and treated with indicated concentrations of inﬂiximab for 5 days. Error bars indicate s.d. of two independent experiments. b Levels of
TNFα, IL-6, IL-8 and IL-10 secretion upon BRCA2 depletion. After 0, 2 or 4 days of doxycycline treatment, medium was harvested. TNFα was measured
using ELISA. IL-6, IL-8 and IL-10 were measured using bead-arrays. Error bars indicate s.d. of two or three independent experiments. c Immunoblotting of
BT-549 cells harboring indicated shRNAs after 0, 2 or 4 days of doxycycline treatment. Levels of p-p38, p-JNK, γH2AX, cleaved PARP (‘cPARP’) and
HSP90 were analyzed. Both JNK isoforms (p46 and p54) are indicated. Dotted lines are used to indicate different shRNAs. d BT-549 cells harboring
indicated shRNAs were treated with doxycycline for the indicated time periods, and analyzed by ﬂow cytometry for p-JNK expression. Gating was
performed as shown in the top panel. Numbers indicate the percentages of living cells stained positive for p-JNK. Error bars indicate s.d. of two independent
experiments. e BT-549 cells were treated as described in d. Cells were analyzed by ﬂow cytometry for cleaved PARP. Gating was performed as shown in
the top panel. Numbers indicate the percentages of living cells stained positive for cleaved PARP. Error bars indicate s.d. of two independent experiments.
Throughout the ﬁgure, P values were calculated using two-tailed Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001
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TNFα, and their viability was not affected by JNK or ASK1
inhibition (Fig. 4e, f, Supplementary Fig. 5f). In contrast, BRCA2-
depleted cells again showed decreased viability upon TNFα
administration. Notably, these effects were dose-dependently
reversed by JNK or ASK1 inhibition (Fig. 4e, f, Supplementary
Fig. 5f). To test if the observed increase in TNFα sensitivity upon
BRCA2 depletion was driven by apoptosis-mediated cell death,
we depleted caspase-3, -8 or -9 using siRNAs (Supplementary
Fig. 5g). Especially depletion of caspase-8 and -9 resulted in
reduced sensitivity to TNFα in BRCA2-depleted cells, while the
viability of control-depleted cells was not signiﬁcantly affected
(Fig. 4g, Supplementary Fig. 5h). Blocking caspase activity using
the broad-spectrum caspase inhibitor zVAD-FMK conﬁrmed the
requirement of caspase activity, as TNFα-induced cell death in
BRCA2-depleted BT-549 and HCC38 cells was signiﬁcantly
rescued by zVAD-FMK treatment (Supplementary Fig. 5i).
Combined, these data point at JNK and ASK1 kinases and
caspase-8 and -9 to drive TNFα-induced cell death upon BRCA2
inactivation.
To check whether increased TNFα sensitivity was selectively
induced by BRCA2 inactivation, BT-549 and HCC38 cells were
depleted for the DNA repair proteins BRCA1 or FANCD2
(Supplementary Fig. 6a,b). Depletion of BRCA1 or FANCD2
decreased long-term survival, comparable to BRCA2 depletion
(Supplementary Fig. 6c). Importantly, depletion of BRCA1 or
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in BT-549 and HCC38 cells (Fig. 4h and Supplementary Fig. 6d).
Of note, induction of replication stress with a non-toxic dose of
hydroxyurea (HU) (Supplementary Fig. 6e, f) also sensitized
TNBC cell lines to recombinant TNFα (Fig. 4i, Supplementary
Fig. 6g). Thus, TNFα sensitivity is not speciﬁc to BRCA2
inactivation, but is also induced by inactivation of BRCA1 or
FANCD2, or chemical induction of replication stress.
BRCA2 inactivation leads to an interferon response. To
investigate how BRCA2 inactivation underlies differential acti-
vation of the TNFα pathway, we assessed global changes in
protein abundance using SILAC-MS (Stable Isotope Labeling by
Amino acids in Cell culture–mass spectrometry) (Fig. 5a).
Labeled (‘heavy’) or unlabeled (‘light’) protein extracts from
BRCA2-depleted or control-depleted BT-549 or HCC38 cells
were mixed and analyzed by mass spectrometry (MS). To control
for potential effects of metabolic labeling, label-swap controls
were included (Fig. 5a). Common differentially expressed pro-
teins measured in at least three out of four independent MS runs
were plotted (Fig. 5b, Supplementary Data 3). Interestingly,
depletion of BRCA2 resulted in a common set of upregulated
proteins (Fig. 5c). When the top 25 upregulated proteins were
analyzed using gene set enrichment, a clear enrichment for
interferon-α and interferon-γ pathways was found (Fig. 5c).
Because mass spec proteomics only captures a subset of the
proteome, we validated these observations using gene expression
proﬁling. To this end, gene set enrichment analysis was per-
formed on RNA-sequencing (RNAseq) data derived from
control-depleted or BRCA2-depleted BT-549 or HCC38 cells
(Fig. 5d–g). Clearly, the most signiﬁcantly enriched gene sets in
both cell lines included interferon-γ and interferon-α responses,
as well as activation of TNFα-responsive pathways (Fig. 5d–g, and
Supplementary Fig. 7a,b).
cGAS/STING-dependent TNFα sensitivity upon BRCA2 loss.
Previous studies from us and others have demonstrated that
defective DNA repair can lead to aberrant mitoses and
micronuclei36,37. Recently, cells harboring micronuclei were
shown to express a distinct gene expression proﬁle, character-
ized by cGAS/STING (cyclic GMP-AMP synthase/stimulator of
interferon genes)-dependent interferon signaling38. RNAseq
analysis of BRCA2-depleted BT-549 and HCC38 cells showed a
signiﬁcant enrichment for this ‘interferon-stimulated geneset’
(Fig. 6a)38. In line with this notion, we observed elevated levels
of micronuclei and cGAS-positive micronuclei upon BRCA2
depletion in BT-549 and HCC38 cells (Fig. 6b, c), which was
accompanied by elevated levels of phosphorylated signal
transducer and activator of transcription 1 (STAT1), a key
mediator of interferon-induced transcription (Fig. 6d, Supple-
mentary Fig. 7c). Importantly, siRNA-mediated depletion of
cGAS or STING resulted in reduced levels of STAT1 phos-
phorylation in BRCA2-depleted BT-549 and HCC38 cells
(Fig. 6e, f and Supplementary Fig. 7d,e). Furthermore, depletion
of cGAS or STING rescued the sensitivity of TNFα upon
BRCA2 inactivation in BT-549 and HCC38 cells (Fig. 6g and
Supplementary Fig. 7f). These results were conﬁrmed in BT-549
cells in which cGAS was mutated using CRISPR/Cas9. Speci-
ﬁcally, mutation of cGAS rescued long-term viability in
BRCA2-depleted cells (Supplementary Fig. 7g,h). Also, TNFα
sensitivity and STAT1 phosphorylation upon BRCA2 depletion
were rescued in cGAS−/− cells compared to cGAS wt cells
(Fig. 6h,i and Supplementary Fig. 7i,j). Combined, these data
show that BRCA2 inactivation instigates a cGAS/STING-
dependent pro-inﬂammatory response which enhances TNFα
sensitivity (Fig. 7).
Discussion
DNA repair defects facilitate genome instability and the ensuing
accumulation of cancer-promoting mutations39. Indeed, inherited
or somatic mutations in DNA repair genes are frequently
observed in cancer1. Yet, defective DNA repair compromises
cellular viability, and it remains incompletely clear how (tumor)
cells respond to loss of DNA repair pathways. In this study, we
describe a prominent transcriptional interferon response upon
BRCA2 inactivation, which can be ascribed to genome instability
and ensuing cytoplasmic DNA. This response leads to wide-
spread cellular re-wiring, including enhanced sensitivity to TNFα.
This latter feature was the basis on which TNFRSF1A (encoding
TNFR1) and KHDRBS1 (encoding SAM68) were identiﬁed to
rescue cell death in BRCA2-depleted KBM-7 cells. Speciﬁcally,
HR-deﬁciency instigates the production of pro-inﬂammatory
cytokines, including TNFα, which activates TNFα receptor-
mediated cell death. Interference with the cytosolic DNA sensor
cGAS/STING, the TNFα-receptor, or its downstream signaling
components rescued TNFα-induced cell death in BRCA2-
depleted cells.
TNFα signaling has previously been described to context-
dependently promote cellular survival or promote apoptosis34.
We ﬁnd that TNFα signaling in the context of accumulated DNA
damage exerts pro-apoptotic effects, either in the context of
defective DNA repair or through HU-induced replication stress.
These conditions have in common that they induce micronuclei,
which were recently shown to be a source of cytoplasmic
DNA38,40. cGAS/STING activation was previously described to
instigate a cell-intrinsic interferon response, resulting in STAT
signaling41. Indeed, BRCA2 depletion induced cGAS-positive
micronuclei, along with increased levels of phosphorylated
Fig. 4 BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h
and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or
SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38
and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα
concentrations for 5 days. d DLD-1 wt or BRCA2−/− cells were plated and treated for 5 days with indicated TNFα concentrations. e, f BT-549 cells
harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence
or absence of JNK inhibitor (e) or ASK1 inhibitor (f) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for
24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars
represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t-test. *P <
0.05, ***P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and
treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and
indicated TNFα concentrations for 5 days. Throughout the ﬁgure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least
three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using
two-tailed Student’s t-test. For P values, see Supplementary Data 4
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STAT1 (Fig. 6). The observed cellular re-wiring resulted in
enhanced TNFα sensitivity, which depended on ASK1 and JNK
kinases as well as caspase-8 and -9. Our observation that multiple
caspases are involved in TNFα-mediated cell death in BRCA2-
defective cells is in line with caspase-8 being engaged in TNFα-
mediated apoptosis42, caspase-9 being involved in intrinsic, DNA
damage-induced apoptosis43 and caspase-3 being a common
downstream factor in programmed cell death.
Our ﬁndings are also in good agreement with previous reports
of increased transcription of TNFα upon irradiation44, enhanced
sensitivity of FANC-C mutant cells to TNFα45, irradiation-
induced re-wiring of TNFα signaling which limited cellular sur-
vival46 and STING activation in response to S-phase DNA
damage47. Furthermore, treatment with recombinant TNFα was
shown to sensitize cancer cells for genotoxic agents48.
Multiple other mutations have previously been described to
rescue cell death upon loss of homologous recombination genes.
Most of these mutations (including TP53BP1, MAD2L2, HELB and
RIF1 and Shieldin complex members) could rescue cell death and
PARP1 inhibitor sensitivity induced by inactivation of BRCA1 but
not BRCA2, which is likely due to BRCA2 functioning downstream













Light medium Heavy medium
Arg-0 Lys-0 Arg-10 Lys-6
48 h doxycyclin
Mix protein fractions 1:1
shLUC L vs shBRCA2 H

















Regulation of INFG signaling
Interferon signaling
Glycogen synthesis
Growth hormone receptor signaling









































Hallmark: interferon gamma response
FDR q value = 0.0096
NES = 1.62
















FDR q value = 0.0001
NES = 1.85
Gene rank in ordered dataset

































Fig. 5 Proteomic and transcriptomic analysis reveals upregulation of pro-inﬂammatory genes upon BRCA2 depletion. a Workﬂow of SILAC-MS analysis of
BT-549 and HCC38 cell lines with indicated shRNAs. b Log2 ratios (heavy vs light) of proteins that were measured in at least three out of four independent
MS analyses in BT-549 (left panel) or HCC38 (right panel) cells. Black dots represent the mean of log2 ratios from three or four experiments. c ENRICHR
was used to analyze pathway enrichment in top 25 upregulated proteins in response to BRCA2 depletion in BT-549 cells and HCC38 cells. The top 10
enriched Reactome datasets are displayed. d, e RNA sequencing was performed on BT-549 and HCC38 cells harboring shLUC or shBRCA2 #2, treated for
72 h with or without doxycycline. Gene set enrichment analysis (GSEA) using ‘Hallmark’ gene sets showed enrichment of Interferon Gamma response (d)
and TNFA signaling via NF-κB (e) in BRCA2-depleted cells. f, g Top 10 enriched Hallmark gene sets in BRCA2-depleted BT-549 (f) and HCC38 (g) cells
compared to control cell lines. The top 10 list of enriched pathways can be found in Supplementary Fig. 7a
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(encoding PTIP) was shown to rescue cell death induced by BRCA2
mutation27. PAXIP1 was identiﬁed in our screen, albeit less sig-
niﬁcantly enriched when compared to TNFR1 and SAM68.
Constitutive NF-κB activation is described to often occur in
different types of cancers, and is associated with aggressive tumor
growth and therapy resistance51. Recently, and in line with our
observations, cancer-associated genomic instability was shown to
drive NF-κB activation through a cytosolic DNA response52. Such
NF-κB activity might be accompanied with autocrine TNFα
secretion, as has been demonstrated for head-and-neck cancers53.
NF-κB activation was previously described in response to DSB
formation, where it provides an initial cellular stress response to
DNA damage54,55. Paradoxically, sustained levels of DNA
damage (in our models caused by BRCA2 deﬁciency) lead to
prolonged JNK activation, which is normally suppressed by NF-
κB56,57. Consequently, sustained JNK signaling can promote pro-
apoptotic signaling upon TNFα-induced TNFR1 activation58,59.
TNFα, in analogy to NF-κB signaling, has also been described
to play a role in cancer. Recombinant TNFα was shown to induce
cancer cell senescence when combined with interferon-γ treat-
ment, and was demonstrated to induce tumor cell death in
metastatic melanoma via isolated limb perfusion60,61. Our
observations of TNFα sensitivity of BRCA2-defective cancer cells
suggest that BRCA2 mutant tumors may be selectively sensitive to
TNFα. Unfortunately, development of TNFα-based treatment
modalities was not successful due to toxicity62. Conversely, our
p-STAT1
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data suggest that modulation of TNFα or cGAS/STING signaling
may allow survival of BRCA-deﬁcient tumor cells, and warrants
care in using TNFα antagonists in BRCA mutation carriers.
Methods
Cell culture. KBM-7, BT-549, HCC38, MDA-MB-231 and HEK293T cells were
obtained from ATCC. DLD-1 human colorectal adenocarcinoma cells were from
Horizon (Cambridge, UK). MEFs harboring the Brca2sko allele were a kind gift of
Jos Jonkers and Peter Bouwman (Netherlands Cancer Institute, Amsterdam, The
Netherlands). Human near-haploid KBM-7 cells were cultured in Iscove’s modiﬁed
Dulbecco’s medium. MDA-MB-231 breast cancer cells, 293T human embryonic
kidney cells, DLD-1 cells and mouse embryonic ﬁbroblasts were cultured in Dul-
becco’s modiﬁed Eagle’s medium. BT-549 and HCC38 were cultured in Roswell
Park Memorial Institute (RPMI) medium. Growth media for each line were sup-
plemented with 10% fetal calf serum and penicillin/streptomycin (100 units per
mL). All human cell lines were cultured at 37 °C in a humidiﬁed incubator supplied
with 5% CO2. MEFs were cultured in a low-oxygen (1% O2) incubator. For stable
isotope labeling, BT-549 or HCC38 cells harboring shLUC and shBRCA2 #2 were
cultured for at least four cell passages (~14 days) in RPMI medium with unmo-
diﬁed arginine (Arg) and Lysine (Lys) (Light ‘L’) or with stable isotope-labeled
Arg10 and Lys6 (Heavy ‘H’) (Silantes).
Viral transduction. To generate KBM-7 and breast cancer cell lines with
doxycycline-inducible shRNAs, cells were infected with Tet-pLKO-puro, harboring
shRNAs directed against luciferase (‘shLUC’, 5′-AAGAGCTGTTTCTGAGGA
GCC-3′), KIF11 (5′- CACGTACCCTTCATCAAATTT-3′), BRCA2 (#1 5′-GAA-
GAATGCAGGTTTAATA-3′ and #2 5′-AACAACAATTACGAACCAAACTT-3′),
BRCA1 (#1 5′-CCCACCTAATTGTACTGAATT-3′ and #2 5′-GAGTATGCAA
ACAGCTATAAT-3′) and FANCD2 (#1 5′-AAGGGAGAAGTCATCGAAGT
A-3′ and #2 5′-GGAGATTGATGGTCTACTAGA-3′). Tet-pLKO-puro was a gift
from Dmitri Wiederschain (Addgene plasmid #21915)63.
To validate hits from the genetic screens, KBM-7, MEFs and breast cancer cells
were transduced with pLKO.1 vectors, which in addition to the shRNA cassette
either carried an IRES mCherry cassette (pLKO.1-mCherry, a kind gift from Jan
Jacob Schuringa (UMCG, The Netherlands)) or a puromycin resistance cassette
(pLKO.1-puro, a gift from David Root, Addgene plasmid #10878)64. Both pLKO.1
plasmids were used as described previously30. shRNAs against TNFRSF1A and
KHDRBS1 were cloned into pLKO.1 vectors using the Age1 and EcoR1 restriction
sites. The shRNA targeting sequences that were used are: TNFRSF1A (#1, 5′-GG
AGCTGTTGGTGGGAATATA-3′ and #2, 5′-TCCTGTAGTAACTGTAAGAA
A-3′), KHDRBS1 (#1, 5′-ACCCACAACAGACAAGTAATT-3′ and #2, 5′-GAT
GAGGAGAATTACTTGGAT-3′) and SCR (5′-CAACAAGATGAAGAGCACC
AA-3′). For MEF cells, shRNA sequences used were for TNFRSF1A (5′-GGCTC
TGCTGATGGGGATACA-3′), KHDRBS1 (5′-GACGAGGAGAATTATTTGGA
T-3′) and SCR (5′-CAACAAGATGAAGAGCACCAA-3′). Lentiviral particles
were produced as described previously30. In brief, HEK293T packaging cells were
transfected with 4 μg pLKO.1 DNA in combination with the packaging plasmids
lenti-VSV-G and lenti-ΔYPR using a standard calcium phosphate protocol. Virus-
containing supernatant was harvested at 48 and 72 h after transfection and ﬁltered
through a 0.45 μM syringe ﬁlter with the addition of 4 μg per mL polybrene.
Supernatants were used to infect target cells in three consecutive 12 h periods.
MEFs were transduced with pRetroSuper retrovirus as described previously23.
Brieﬂy, HEK293T cells were grown to 70% conﬂuency and transfected with 10 μg
retroviral vector encoding ‘Hit-and-run’ Cre recombinase together with Gag-Pol
packaging and VSV-G65. Supernatants were harvested at 48 and 72 h after
transfection and ﬁltered through a 0.45 μM syringe ﬁlter. MEFs were plated and
infected for 24 h with retroviral supernatant with an additional second and third
round of infection after 24 and 32 h. At 24 h after the last infection, cells were
washed and cultured in fresh medium with puromycin (2 μg per mL) for 48 h.
Switching of the conditional sko allele upon Cre retrovirus, resulting in a 110 base-
pair fragment, was shown by PCR ampliﬁcation of genomic DNA with the
following primers: 5′-GTG GGC TTG TAC TCG GTC AT-3′ (forward) and 5′-
GTA ACC TCT GCC GTT CAG GA-3′ (reverse).
Generation of cGAS knockout cells by the CRISPR/Cas9 system. CRISPR
guide RNAs were generated against cGAS (#1 caccgGGCATTCCGTGCG-
GAAGCCT; #2 caccgTGAAACGGATTCTTCTTTCG) and cloned into the Cas9
plasmid using the AgeI and EcoRI restriction sites. The pSpCas9(BB)−2A-Puro
V2.0 (PX459) was a gift from Feng Zhang (Addgene plasmid #62988)66. BT-549
cells were transfected with both guide RNA plasmids simultaneously (2 μg) using
FuGene (Promega) according to the manufacturer’s instructions. After transfec-
tion, cells were selected with puromycin (1 μg per mL) for 2–3 days. Single cell
cGAS−/− clones were conﬁrmed by immunoblotting. Subsequently, cGAS−/− or
parental cells were infected with Tet-pLKO-puro shRNAs targeting BRCA2 or
Luciferase as described before.
Gene-trap mutagenesis and mapping of insertion sites. KBM-7 cells were
infected with pLKO.1-tet-puro-BRCA2 #2 and puromycin-resistant clones were
sorted into monoclonal cell lines. The resulting monoclonal KBM-7-shBRCA2 #2
cell line was mutagenized using retroviral infection as described previously67. In
short, approximately 64 × 10E6 KBM-7 cells were retrovirally infected with the
gene-trap vector pGT, containing a strong splice acceptor. After three consecutive
rounds of infection, an ~75% infection rate was achieved based on green ﬂuor-
escent protein positivity. All mutagenized cells were pooled and 20 × 10E6 cells
were treated with 1 μg per mL doxycycline. At 5 days after doxycycline addition,
cells were plated at 20,000 cells per well in 40 96-well plates to allow competitive
selection for 14 days. Subsequently, cell pellets were frozen and DNA was isolated.
Viral insertions were ampliﬁed using LAN PCR, identiﬁed by massive parallel
Fig. 6 Micronuclei formation and cGAS/STING-dependent STAT1 activation upon BRCA2 depletion. a GSEA shows signiﬁcant enrichment of interferon-
stimulated genes in BRCA2-depleted BT-549 (left panel) or HCC38 (right panel) cells. b BT-549 and HCC38 cell lines harboring shLUC or shBRCA2 #2
were treated with doxycycline for 4 days, and stained with anti-cGAS and DAPI. Scale bar represents 15 μm. c Quantiﬁcation of cGAS-positive micronuclei
as described in b. ≥300 Cells were counted per condition. Error bars indicate s.e.m. of six independent experiments. P values were calculated using two-
tailed Student’s t-test. **P < 0.01, ***P < 0.001, ****P < 0.0001. d BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for indicated
time periods. Phosphorylation status of STAT1 was analyzed by immunoblotting. e BT-549 cells harboring shLUC or shBRCA2 #2 were transfected with
indicated siRNAs. Levels of cGAS and STING were analyzed by immunoblotting at 5 days post transfection. f BT-549 cells harboring shLUC or shBRCA2
cells were transfected with indicated siRNAs for 24 h, and subsequently treated with doxycycline for 48 h. Phosphorylation status of STAT1 was analyzed
by immunoblotting. g BT-549 cells harboring shLUC or shBRCA2 cells were transfected with indicated siRNAs for 24 h. Cells were re-plated and treated
with doxycycline for 48 h, followed by treatment with indicated TNFα concentrations for 5 days. h cGAS−/− or wt BT-549 cells with indicated shRNAs
were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. i cGAS−/− or wt BT-549 cells with
shBRCA2 #2 were treated with doxycycline for indicated time periods. Phosphorylation status of STAT1 and expression of cGAS were analyzed by
immunoblotting. For g, h, cell viability was assessed by MTT conversion. Error bars indicate s.e.m. of at least three independent experiments with three
































Fig. 7 Schematic model of inﬂammatory signaling upon BRCA2 inactivation.
BRCA2 inactivation (1) leads to micronuclei formation (2) and cGAS/
STING-dependent activation of an interferon response (3). This leads to
pro-inﬂammatory cytokines production, and sensitivity to TNFα, in a TNFR/
SAM68 (4) and ASK1/JNK-dependent fashion (5)
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sequencing and mapped to the human genome as described previously68. DNA
sequencing data are available at the NCBI short read archive (PRJNA299537).
Western blotting. Knockdown efﬁciencies and biochemical responses were ana-
lyzed by western blotting. Cells were lysed in Mammalian Protein Extraction
Reagent (MPER, Thermo Scientiﬁc), supplemented with protease inhibitor and
phosphatase inhibitor cocktail (Thermo Scientiﬁc). Separated proteins were
transferred to polyvinylidene ﬂuoride membranes and blocked in 5% milk in Tris-
buffered saline, with 0.05% Tween-20. Immunodetection was done with antibodies
directed against BRCA2 (1:1000, Calbiochem, #OP95), TNFR1 (1:500, Cell Sig-
naling, #3736; 1:1000, Santa Cruz, sc-8436), SAM68 (1:1000, Santa Cruz, sc-333),
BRCA1 (1:1000, Cell Signaling, #9010), FANCD2 (1:200, Santa Cruz, sc-20022),
phospho-JNK (1:1000, Cell Signaling, #9251), phospho-p38 (1:1000, Cell Signaling,
#4511), cleaved PARP (1:1000, Cell Signaling, #5625), γH2AX (1:1000, Cell Sig-
naling, #9718), phospho-STAT1 (1:1000, Cell Signaling, #9167, #8826), HSP90
(1:1000, Santa Cruz, #sc-69703), cGAS (1:1000, Cell Signaling, #15102), STING
(1:1000, Cell Signaling, #13647), caspase-3 (1:1000, Cell Signaling, #9662), caspase-
8 (1:1000, Enzo, #ALX-804-242), caspase-9 (1:1000, Cell Signaling, #9502) and
beta-Actin (1:10,000, MP Biochemicals, #69100). Appropriate horseradish
peroxidase-conjugated secondary antibodies (1:2500, DAKO) were used and sig-
nals were visualized with enhanced chemiluminescence (Lumilight, Roche diag-
nostics) on a Bio-Rad Bioluminescence device, equipped with Quantity One/
Chemidoc XRS software (Bio-Rad). Uncropped versions of all western blots can be
found in Supplementary Fig. 8–13.
Quantitative RT-qPCR. Cell pellets from KBM-7-shBRCA2 #1, KBM-7-shBRCA2
#2 or KBM-7-shLUC treated with doxycycline (1 μg per mL) for 0 or 4 days were
harvested. Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and
complementary DNA (cDNA) was synthesized using SuperScript III (Invitrogen)
according to the manufacturer's instructions. Quantitative reverse transcription-
PCR (RT-PCR) for BRCA2 mRNA expression levels was performed in triplicate
using the following oligos: 5′-TTGTTTCTCCGGCTGCAC-3′ (forward) and 5′-
CGTATTTGGTGCCACAACTC-3′ (reverse). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as a reference and experiments were performed on
an Applied Biosystems Fast 7500 machine. Alternatively, KBM-7-shBRCA2 #2 cells
were pre-treated with doxycycline for 24 h prior to transfection with 40 nM
SUPTH3 siRNA (Thermo Scientiﬁc; ON-TARGETplus SMART pool, #L-019548-
00) or 'medium GC duplex' control siRNA (Life Technologies, #12935-300). At 72
h after siRNA transfection, cell pellets were harvested and BRCA2 mRNA levels
were determined as above.
Immunoﬂuorescence microscopy. KBM-7 cells were left untreated or were irra-
diated using a Cesium137 source (CIS international/IBL 637 irradiator, dose rate:
0.01083 Gy per second). After 3 h, cells were washed in phosphate-buffered saline
(PBS) and then ﬁxed in 2% paraformaldehyde with 0.1% Triton X-100 in PBS for
30min at room temperature. Cells were permeabilized in 0.5% Triton X-100 in PBS
for 10 min. Subsequently, cells were extensively washed and incubated with PBS
containing 0.05% Tween-20 and 4% bovine serum albumin (fraction V) (PBS-
Tween-BSA) for 1 h to block nonspeciﬁc binding. For micronuclei staining, BT-549
and HCC38 cells were grown on coverslips and treated with doxycycline for 4 days.
Cells were ﬁxed in 4% paraformaldehyde for 15 min at room temperature. Subse-
quently, cells were permeabilized with 0.1% Triton X-100 in PBS for 1 min followed
by blocking in 0.05% Tween-20 and 2.5% BSA in PBS for 1 h. Cells were incubated
overnight at 4 °C with primary antibodies targeting RAD51 (GeneTex, GTX70230,
1:400), γH2AX (Cell Signaling, #9718, 1:100) or cGAS (Cell Signaling, #15102,
1:200) in PBS–Tween–BSA. Cells were extensively washed and incubated for 1 h
with Alexa-conjugated secondary antibodies (1:400) and counterstained with 4′,6-
diamidino-2-phenylindole (DAPI). Slides were mounted with ProLong Antifade
Mountant (Thermoﬁsher). Images were acquired on a Leica DM-6000RXA ﬂuor-
escence microscope, equipped with Leica Application Suite software.
DNA ﬁber assay. To assess replication fork protection during replication stress,
KBM-7-shBRCA2 #2 cells were pre-treated with doxycycline (1 μg per mL) for 96
h, and then pulse-labeled with chloro-deoxyuridine (CIdU, 50 µM) for 40 min.
Subsequently, cells were washed with medium and incubated with HU (2 mM) for
4 h. Cells were lysed on microscopy slides in lysis buffer (0.5% sodium dodecyl
sulfate (SDS), 200 mM Tris (pH 7.4), 50 mM EDTA). DNA ﬁbers were spread by
tilting the slide and were subsequently air-dried and ﬁxed in methanol/acetic acid
(3:1) for 10 min. Fixed DNA spreads were stored for 24 h at 4 °C, and prior to
immuno-labeling, spreads were treated with 2.5 M HCl for 1.5 h. CIdU was stained
with rat anti-BrdU (1:750, AbD Serotec) for 2 h and slides were further incubated
with AlexaFluor 488-conjugated anti-rat IgG (1:500) for 1.5 h. Images were
acquired on a Leica DM-6000RXA ﬂuorescence microscope, equipped with Leica
Application Suite software. The lengths of CIdU and IdU tracks were measured
using ImageJ software.
Flow cytometry. To measure changes in the fraction of shRNA-containing
mCherry-positive cells, cells were re-plated every 3 or 4 days. At those time points,
approximately 25% of the culture was used to measure the percentage of mCherry-
positive cells by ﬂow cytometry, whereas the remaining cells were re-plated for
further time points. If indicated, cells were treated with doxycycline (1 μg per mL)
or ethanol as a solvent control. At least 10,000 (BT-549) or 30,000 (KBM-7) events
were analyzed per sample on an LSR-II (Becton Dickinson). Cells, pre-treated with
doxycycline (1 μg per mL) or HU, were harvested at different time points, washed
and ﬁxed in ice-cold 70% ethanol. Cells were permeabilized and blocked with
PBS–1% BSA–0.05% Tween-20 or with PBS–2% BSA–0.1% Triton for 1 h and
stained with rabbit anti-cleaved PARP (1:100, Cell Signaling, #5625), rabbit anti-
phospho-SAPK/JNK (Thr183/Tyr185) (1:100, Cell Signaling, #9251), rabbit anti-
TNFR1 (1:100, Abcam, #19140) or rabbit anti-γH2AX (1:100, Cell Signaling,
#9718) overnight at 4 °C. Samples were subsequently stained with AlexaFluor 488-
conjugated goat anti-rabbit secondary antibody (1:400) for 1 h and analyzed on a
FACS Calibur (Becton Dickinson). Data were analyzed with FlowJo software.
Clonogenic survival assays. BT-549 cells or MEFs were plated in 6-well plates
(1000 cells per well) and treated with doxycycline (1 μg per mL) or recombinant
TNFα as indicated. MEFs were pre-infected with retroviral ‘Hit-and-run’ Cre
recombinase and selected with puromycin (2 μg per mL). After 14 days, cells were
ﬁxed in 4% formaldehyde–PBS and stained with 0.1% crystal violet in H2O. Clo-
nogenic assays were measured and quantiﬁed using an EliSpot reader (Alpha
Diagnostics International) with vSpot Spectrum software.
MTT assays. KBM-7, MDA-MB-231, BT-549, HCC38 and MEF cells were plated
in 96-wells plates (600–1000 cells per well), and pre-treated with or without dox-
ycycline (1 μg per mL) for 2 days. MEFs were pre-infected with retroviral ‘Hit-and-
run’ Cre recombinase and selected with puromycin (2 μg per mL). If indicated, BT-
549 and HCC38 cells were transfected with siRNAs for 24–48 h prior to plating cells
in 96-well plates. Speciﬁcally, cells were transfected with siRNA smartpools (ﬁnal
concentration 100 nM), targeting cGAS (#015607, Dharmacon), STING (#024333,
Dharmacon), caspase-3 (#29237, Santa Cruz), caspase-8 (#29930, Santa Cruz),
caspase-9 (#29931, Santa Cruz) or a negative control sequence (#12935300, Ther-
moﬁsher) using oligofectamine (Invitrogen), according to the manufacturer’s
guidelines. Cells were treated with indicated concentrations of the following agents:
Inﬂiximab (Merck, Sharp and Dome), HU (Sigma), ASK1 inhibitor NQDI-1 (Axon
Medchem, #2179), JNK inhibitor SP600125 (Selleck Chemicals, #S1460), Pan cas-
pase inhibitor (Z-VAD-FMK, Promega) and/or recombinant TNFα (Thermoﬁsher).
After 5 days of treatment, methyl thiazol tetrazolium (MTT) was added to a ﬁnal
concentration of 5 mg per mL for 4 h. Medium was removed and formazan crystals
were dissolved in dimethyl sulfoxide (DMSO). The absorbance was measured at
520 nm with a Bio-Rad iMark spectrometer. Cell viability was calculated as the
relative value in signal compared to DMSO or untreated cells. Unless mentioned
otherwise, statistical signiﬁcance was tested using two-sided Student’s t-tests.
Cytokine analysis. To analyze excreted TNFα levels, KBM-7-shBRCA2 or KBM-7-
shLUC cells were treated with doxycycline (1 μg per mL) for 48 h. Proteins in
supernatant culture media were concentrated using Microcon-30 kDa centrifugal
ﬁlter units with Ultracel-30 membrane (Millipore). Subsequently, TNFα con-
centrations were determined using a human TNFα ELISA kit (KHC3011, Life
Technologies).
IL-6, IL-8 and IL-10 levels were analyzed using the Human Inﬂammatory
Cytokine Kit (BD Bioscience, #551811), according to the manufacturer’s protocol.
In short, media were collected from BT-549 cells harboring different shRNAs, after
treatment with doxycycline for 0, 2 or 4 days. Media samples (50 μL per sample)
were incubated with IL-6, IL-8 and IL-10 capture beads for 3 h at room
temperature. After two wash steps, samples were measured on an LSR-II (Becton
Dickinson). Data were analyzed using FlowJo software, and cytokine
concentrations were calculated using cytokine standards (BD Bioscience).
In-gel digestion and liquid chromatography/tandem mass spectrometry. BT-
549 cells and HCC38 were cultured in light (‘L’) or heavy (‘H’) SILAC media and
were treated with doxycycline for 48 h. Cells were harvested and lysed in NP-40
buffer (20 mM Tris pH 7.4, 150 mM NaCl, 0.2% v/v Igepal, 10% glycerol) sup-
plemented with a protease/phosphate inhibitor cocktail (Thermoﬁsher). Protein
concentrations were determined using Bradford assay and 50 μg of proteins from
shLUC-‘L’ cells was mixed with shBRCA2 #2-‘H’ cells and vice versa. Proteins were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE). Gel lanes were cut into slices for in-gel digestion. Slices were cut into 1 mm
pieces and destained with 100 mM ammonium bicarbonate (ABC) in 50–70%
acetonitrile. Reduction (10 mM dithiothreitol in 100 mM ABC) and alkylation (55
mM iodoacetamide in 100 mM ABC) steps were performed to block cysteines. Gel
pieces were dehydrated and incubated overnight with 10 ng per μL trypsin (Pro-
mega), diluted in 100 mM ABC at 37 °C. Peptides were subsequently extracted with
5% formic acid for 20 min.
Online chromatography of the extracted tryptic peptides was performed using
an Ultimate 3000 HPLC system (Thermoﬁsher Scientiﬁc), coupled to a Q-Exactive-
Plus mass spectrometer with a NanoFlex source (Thermoﬁsher Scientiﬁc),
equipped with a stainless-steel emitter. Tryptic digests were loaded onto a 5 mm ×
300 μm internal diameter (i.d.) trapping micro column packed with PepMAP100,
5 μm particles (Dionex) in 0.1% formic acid at the ﬂow rate of 20 μl per min. After
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loading and washing for 3 min, trapped peptides were back-ﬂush eluted onto a 50
cm × 75 μm i.d. nanocolumn, packed with Acclaim C18 PepMAP RSLC, 2 μm
particles (Dionex). Column temperature was maintained at 40 °C. Eluents used
were 100:0 H2O/acetonitrile (volume/volume (V/V)) with 0.1% formic acid (Eluent
A) and 0:100 H2O/acetonitrile (v/v) with 0.1% formic acid (Eluent B). The
following mobile phase gradient was delivered at the ﬂow rate of 300 nL per min:
3–50% of solvent B in 90 min; 50–80% B in 1 min; 80% B during 9 min, and back to
1 % B in 1 min and held at 1% A for 19 min which results in a total run time of 120
min. MS data were acquired using a data-dependent acquisition (DDA) top-12
method dynamically choosing the most abundant not-yet-sequenced precursor
ions from the survey scans (300–1650 Th) with a dynamic exclusion of 20 s. Survey
scans were acquired at a resolution of 70,000 at mass-to-charge (m/z) 200 with a
maximum inject time of 50 ms or AGC 3E6. DDA was performed via higher energy
collisional dissociation fragmentation with a target value of 5 × 10E4 ions
determined with predictive automatic gain control in centroid mode. Isolation of
precursors was performed with a window of 1.6m/z. Resolution for HCD spectra
was set to 17,500 at m/z 200 with a maximum ion injection time of 50 ms.
Normalized collision energy was set at 28. The S-lens RF level was set at 60 and the
capillary temperature was set at 250 °C. Precursor ions with single, unassigned, or
six and higher charge states were excluded from fragmentation selection.
MS data analysis. Mass spectrometry raw ﬁles were processed in MaxQuant
(version 1.5.2.8) containing the integrated Andromeda search engine and searched
against the human proteome downloaded from the UniProt database (20,197
entries), using a false discovery rate of 0.01 at the protein and peptide level. Mul-
tiplicity was set to 1 with Lys6 and Arg10 selected as labels. Carbamidomethyl was
set as a ﬁxed modiﬁcation and oxidation of methionine as a variable modiﬁcation.
Default parameters were used for all other settings. Proteins were excluded based on
the criteria ‘marked potential contaminant or reverse protein by MaxQuant’ and
‘only identiﬁed by either light or heavy labeled peptide’. For further analysis, log2 of
protein ratio’s (heavy/light) was calculated. Proteins present in at least 3 out of 4
independent analyses were further analyzed. The full datasets as plotted in Fig. 5b
were used to select upregulated proteins upon BRCA2 depletion, compared to
control shLUC cells. Proteins that were among the top 25 upregulated proteins in
both BT-549 and HCC38 cells were selected. The average level of upregulation in
the BT-549 and HCC38 datasets was used for ENRICHR analysis69.
Gene expression analysis. For indicated genes, mRNA expression levels from the
Ovarian Serous Cystadenocarcinoma TCGA dataset were retrieved from cBio-
portal. Only tumors with sequencing and CNA data (316 samples) were used, and
were subclassiﬁed in ‘BRCA2 wildtype’ (193 samples) and ‘germline BRCA2
mutant’ (25 samples). Of the 25 germline BRCA2 carriers, 2 cases were excluded
because of an additional BRCA1 mutation, resulting in 23 BRCA2 mutant cases. In
the ‘BRCA2 wildtype’ set, only samples were included that did not harbor any
alterations (ampliﬁcation, deletion, mutation, hyper-methylation, mRNA up- or
downregulation) in BRCA1 or BRCA2. Two-sided Student’s t-tests were used to test
for statistically signiﬁcant differences in mRNA expression levels between BRCA2
wt and BRCA2 mutant tumors.
Next-generation RNA sequencing was performed to analyze changes in gene
expression upon BRCA2 depletion. To this end, BT-549 or HCC38 cells harboring
shBRCA2 #2 or shLUC were treated with doxycycline (1 μg per mL) for 72 h. Cells
were harvested and frozen at −80 °C, and RNA was isolated using the mirVANA
kit (Ambion, AM1561). RNA quality was analyzed on microﬂuidic sipper chips
and detected by ﬂuorescence (LabChip GX, Caliper LifeSciences), and samples with
RNA Quality Scores (RQS) > 5 were included for analysis. The QuantSeq RNAseq
3’mRNA kit (Lexogen) was used to generate cDNA libraries for next-generation
sequencing. The cDNA library was puriﬁed and PCR ampliﬁed with Illumina
sequencing adapters were sequenced with 65 base-pair reads on a NextSeq
500 sequencer (Illumina), and generated 7.2 to 19.8 million reads per sample. RNA
sequencing quality control was assessed by FastQC and Samtools Flagstat software.
RNA sequencing data analysis. For gene set enrichment analysis (GSEA), genes
in each cell line were ranked based on the –log P value between doxycycline-treated
shBRCA2 #2 cells and three control settings (shLUC cells and untreated shBRCA2
#2 cells). Genes enriched in BRCA2-depleted cells were positive and genes enriched
in control cells were negative. The ranked gene lists were loaded into GSEA soft-
ware and tested against a set of 280 interferon-induced genes70. Furthermore, gene
sets of the Hallmark collection (MSigDB) were loaded into GSEA and analyzed in
both cell lines. RNA sequencing data are accessible at the GEO repository, under
accession number GSE116943.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
RNA sequencing data are accessible at the GEO repository, under accession
number GSE116943. The mass spectrometry data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identiﬁer PXD007253 (BT-549) and HCC38. DNA sequencing data are available at
the NCBI short read archive (PRJNA299537). Other data from this study are
available from the corresponding author upon request.
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